229 related articles for article (PubMed ID: 1825196)
1. [The immunobiology of transplant rejection and its pharmacological modification].
Köhler H; Zanker B; Strom TB
Dtsch Med Wochenschr; 1991 Feb; 116(7):264-9. PubMed ID: 1825196
[No Abstract] [Full Text] [Related]
2. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
Transplant Proc; 1993 Feb; 25(1 Pt 1):820-2. PubMed ID: 7679844
[No Abstract] [Full Text] [Related]
3. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
Li PK; Nicholls MG; Lai KN
Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
[No Abstract] [Full Text] [Related]
4. Graft failure after T cell-depleted bone marrow transplantation: clinical and immunological characteristics and response to immunosuppressive therapy.
Bunjes D; Wiesneth M; Hertenstein B; Schmeiser T; Arnold R; Heit W
Bone Marrow Transplant; 1990 Nov; 6(5):309-14. PubMed ID: 1705459
[TBL] [Abstract][Full Text] [Related]
5. The clinical role of OKT3.
Norman DJ
Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive drugs for kidney transplantation.
Halloran PF
N Engl J Med; 2004 Dec; 351(26):2715-29. PubMed ID: 15616206
[No Abstract] [Full Text] [Related]
7. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
Ippoliti G; Fronterrè A
Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
[No Abstract] [Full Text] [Related]
9. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies.
Woodle ES; Thistlethwaite JR; Jolliffe LK; Ghobrial I; Fuccello AJ; Stuart FP; Bluestone JA
Transplant Proc; 1991 Feb; 23(1 Pt 1):81-2. PubMed ID: 1824999
[No Abstract] [Full Text] [Related]
10. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
[No Abstract] [Full Text] [Related]
11. Progress in monoclonal antibodies in clinical transplantation.
Cosimi AB
Transplant Proc; 1994 Aug; 26(4):1943-4. PubMed ID: 7915057
[No Abstract] [Full Text] [Related]
12. The potential role of therapeutic antibodies in the regulation of rejection.
Ettenger RB; Yadin O
Transplant Proc; 1995 Oct; 27(5 Suppl 1):13-7. PubMed ID: 7482810
[No Abstract] [Full Text] [Related]
13. [HLA mismatch and graft rejection].
Matsuyoshi H; Senju S; Monji M; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():621-31. PubMed ID: 15861720
[No Abstract] [Full Text] [Related]
14. Acute kidney graft rejection. A morphological and immunohistological study on "zero-hour" and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules.
Andersen CB; Ladefoged SD; Larsen S
APMIS; 1994 Jan; 102(1):23-37. PubMed ID: 7513171
[TBL] [Abstract][Full Text] [Related]
15. New immunosuppressive therapies in renal transplantation: monoclonal antibodies.
Buhaescu I; Segall L; Goldsmith D; Covic A
J Nephrol; 2005; 18(5):529-36. PubMed ID: 16299678
[TBL] [Abstract][Full Text] [Related]
16. The required interaction between monocytes and peripheral blood T lymphocytes (T-PBL) upon activation via CD2 or CD3. Role of HLA class I molecules from accessory cells and the differential response of T-PBL subsets.
Huet S; Boumsell L; Dausset J; Degos L; Bernard A
Eur J Immunol; 1988 Aug; 18(8):1187-94. PubMed ID: 2901355
[TBL] [Abstract][Full Text] [Related]
17. Human T cell activation: participation of Tll antigen (CD2, T,gp.50) in T cell-accessory cell interactions.
Suthanthiran M
Transplant Proc; 1987 Feb; 19(1 Pt 1):336-7. PubMed ID: 2908550
[No Abstract] [Full Text] [Related]
18. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
Hirsch R; Bluestone JA; Bare CV; Gress RE
Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
[No Abstract] [Full Text] [Related]
19. OKT3 resistant rejection in liver transplant patients.
Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
[No Abstract] [Full Text] [Related]
20. Two-signal model for T-cell activation: molecular mechanisms.
Sehajpal PK; Sharma VK; Stenzel KH; Suthanthiran M
Transplant Proc; 1993 Feb; 25(1 Pt 1):104-5. PubMed ID: 8094907
[No Abstract] [Full Text] [Related]
[Next] [New Search]
